MedPath

Vancomycin Shows Promise in Treating PSC-Associated Inflammatory Bowel Disease

• A University of Birmingham study reveals that vancomycin, a common antibiotic for diarrhea, achieved 80% clinical remission in patients with PSC-associated inflammatory bowel disease after four weeks of treatment.

• All study participants demonstrated complete mucosal healing, with significant decreases in inflammatory markers, suggesting a potential breakthrough for patients with combined IBD and autoimmune liver disease.

• Researchers are now preparing for a randomized controlled trial to further investigate vancomycin's therapeutic potential in treating PSC-IBD, a condition that increases risks of colon surgery, cancer, and liver transplantation.

In a groundbreaking discovery, researchers at the University of Birmingham have found that vancomycin, an antibiotic commonly prescribed for diarrhea, could offer new hope for patients suffering from a specific type of inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC).

Clinical Trial Results

The preliminary study demonstrated remarkable efficacy, with 80% of participants achieving clinical remission after a four-week course of oral vancomycin. Notably, all patients exhibited mucosal healing, accompanied by a significant reduction in inflammatory markers. The treatment protocol involved a four-week administration period, followed by a four-week observation phase after discontinuation.

Disease Impact and Significance

PSC-IBD represents a particularly challenging combination of conditions, with most PSC patients developing IBD, while up to 14% of IBD patients develop PSC. This combination significantly elevates patients' risks for requiring colon surgery, developing colon or liver cancer, needing liver transplantation, and facing increased mortality rates.

Expert Perspectives

Dr. Palak Trivedi, Associate Professor and Honorary Consultant Hepatologist at the University of Birmingham's Department of Immunology and Immunotherapy, emphasized the importance of the findings: "We are now preparing applications for a randomised controlled trial to determine the therapeutic effects of vancomycin. This next phase of research is crucial to understanding the full potential of vancomycin in PSC-IBD treatment."
Dr. Mohammed Nabil Quraishi, the study's corresponding author, expressed optimism about the results: "Our findings suggest that vancomycin could offer a new therapeutic option for patients with this challenging combination of IBD and autoimmune liver disease. While these results are preliminary, they provide a strong foundation for further research."

Future Research Direction

The promising results have paved the way for more extensive clinical trials. The research team is currently planning randomized controlled trials to further validate vancomycin's therapeutic potential and establish its role in the treatment paradigm for PSC-IBD patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biomerica's inFoods IBS Test Shows Significant Pain Reduction in Clinical Trial, Particularly Effective for IBS-C and IBS-M Patients

Clinical trial results reveal inFoods IBS test achieved 59.6% success rate in reducing abdominal pain through targeted food elimination, compared to 42.2% in control group.
The test demonstrated exceptional efficacy in IBS-C and IBS-M subtypes, with 67.1% and 66% of patients respectively meeting FDA pain reduction targets.

First-in-Human Trial Launches for Novel Extracellular Vesicle Therapy in Crohn's Fistulas

Hudson Institute researchers advance groundbreaking extracellular vesicle treatment derived from amniotic cells into clinical trials for complex perianal Crohn's disease, offering a potential cost-effective alternative to stem cell therapy.
The first-in-human trial will evaluate the safety and efficacy of hAEC-EV therapy in 15 participants with refractory Crohn's perianal fistulas, marking the second human EV trial in Australia.

Biosimilars Prove Safe and Effective for Pediatric IBD Treatment in Large French Study

A comprehensive French study analyzing data from 5,870 pediatric patients with inflammatory bowel disease (IBD) has demonstrated that biosimilars of infliximab and adalimumab are as safe and effective as their original counterparts. The research provides crucial evidence supporting biosimilar use in pediatric IBD patients, where biosimilars represented 76% of infliximab and 29% of adalimumab initiations.

Key Advances in Inflammatory Bowel Disease: New Therapies, Treatment Strategies, and Long-Term Data

Early, intensive 'top-down' therapy with TNF blockers plus immunomodulators shows superior outcomes compared to the traditional 'step-up' approach for newly diagnosed Crohn's disease.
Risankizumab (Skyrizi) and guselkumab (Tremfya) receive FDA approval for ulcerative colitis, offering new options for patients who have not responded well to conventional treatments.

Advanced Combination Therapy Shows Promise for Refractory Pediatric IBD

A recent study suggests that advanced combination therapy may offer a non-surgical option for children and young adults with refractory inflammatory bowel disease (IBD).
The study found that 58.3% of patients achieved steroid-free clinical remission at 6 months with advanced combination therapy, which includes TNF-alpha inhibitors, vedolizumab, ustekinumab, dupilumab and JAK inhibitors.

Infliximab Monotherapy Shows Comparable Efficacy to Combination Therapy in IBD Treatment

Post hoc analysis of LIBERTY trials reveals infliximab monotherapy is as effective as combination therapy for Crohn's disease and ulcerative colitis.
The study included 429 patients, with no significant differences in efficacy outcomes between monotherapy and combination therapy at Week 54 and 102.

Mirikizumab Shows Long-Term Efficacy in Ulcerative Colitis and Crohn's Disease

Mirikizumab, approved for ulcerative colitis, demonstrates sustained clinical remission in 81% of patients over three years in the LUCENT-3 trial.
VIVID-2 trial data reveals that 87% of Crohn's disease patients treated with mirikizumab maintain clinical remission for up to five years.

Tulisokibart Shows Promise in Treating Moderate to Severe Ulcerative Colitis

A Phase 2 trial of tulisokibart, an anti-TL1A monoclonal antibody, demonstrated superior efficacy compared to placebo in inducing clinical remission in patients with moderate to severe ulcerative colitis.
The study utilized a genetic-based diagnostic test to identify patients more likely to respond to tulisokibart, showing improved remission rates in this subgroup.

Vedolizumab: A New Therapeutic Option for Inflammatory Bowel Disease

Vedolizumab, a fully humanised monoclonal antibody, has emerged as a promising treatment for patients with moderate-to-severe ulcerative colitis and Crohn’s disease who are refractory or intolerant to conventional treatments or anti-TNFα agents. This article reviews the efficacy, safety, and tolerability of vedolizumab, highlighting its role in the treatment algorithms for inflammatory bowel disease based on clinical trials and real-world studies.

Alicaforsen Shows Promise in Treating Inflammatory Bowel Disease

Alicaforsen, an ICAM-1 inhibitor, has demonstrated effectiveness in treating ulcerative colitis and shows potential for pouchitis, with ongoing phase 3 trials. Its safety profile in UC patients is favorable, and it has received orphan designation for pouchitis treatment.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy